



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : A61K 9/28, 9/32, 9/36 A61K 9/50, 9/56, 9/58 A61K 9/62		A1	(11) International Publication Number: WO 88/03795 (43) International Publication Date: 2 June 1988 (02.06.88)
(21) International Application Number: PCT/US87/03068 (22) International Filing Date: 24 November 1987 (24.11.87) (31) Priority Application Number: 933,988 (32) Priority Date: 24 November 1986 (24.11.86) (33) Priority Country: US		(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), DK, FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent). Published <i>With international search report.</i>	
(71)(72) Applicant and Inventor: MEHTA, Atul, M. [US/US]; 252 East Crescent Avenue, Ramsey, NJ 07446 (US). (74) Agents: HANLEY, Walter, E., Jr. et al.; Kenyon & Kenyon, One Broadway, New York, NY 10004 (US).			

(54) Title: TASTE-MASKED PHARMACEUTICAL COMPOSITIONS**(57) Abstract**

A pharmaceutical composition comprised of 1) a pharmaceutical core which is further comprised of a pharmaceutically active dose of a compound and, 2) a microencapsulating polymer which coats the pharmaceutical core and is capable of taste-masking the active compound. The polymer coating maintains its integrity, i.e., does not fracture and release active when tabletted and/or chewed, and can provide immediate release of the active compound in the stomach, or alternatively, in certain embodiments, can release the active agent in the upper intestinal tract or in sustained release fashion. Additionally, the polymeric coating compositions or the pharmaceutical core may contain diluents, fillers, bulking agents, and plasticizers. The polymeric coatings may also contain pigments and opacifiers to promote compliance and enhance the storage stability of light sensitive active agents.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT Austria	FR France	ML Mali
AU Australia	GA Gabon	MR Mauritania
BB Barbados	GB United Kingdom	MW Malawi
BE Belgium	HU Hungary	NL Netherlands
BG Bulgaria	IT Italy	NO Norway
BJ Benin	JP Japan	RO Romania
BR Brazil	KP Democratic People's Republic	SD Sudan
CF Central African Republic	of Korea	SE Sweden
CG Congo	KR Republic of Korea	SN Senegal
CH Switzerland	LI Liechtenstein	SU Soviet Union
CM Cameroon	LK Sri Lanka	TD Chad
DE Germany, Federal Republic of	LU Luxembourg	TG Togo
DK Denmark	MC Monaco	US United States of America
FI Finland	MG Madagascar	

-1-

TASTE-MASKED PHARMACEUTICAL COMPOSITIONS

BACKGROUND OF THE INVENTION

5

This invention relates to novel taste-masked pharmaceuticals and to taste-masked pharmaceuticals capable of being chewed without producing a bitter taste. In one embodiment of the invention a 10 pharmaceutical composition comprised of a coated acetaminophen core that masks the bitter and unpleasant taste of acetaminophen is provided. A method of producing chewable tablets incorporating the coated acetaminophen is also described. The coating 15 composition and the method of producing chewable tablets may be modified to provide taste-masking properties to a large number of unpleasant tasting drugs.

In a preferred embodiment of this invention, the 20 formulation comprises a tablet which is further comprised of acetaminophen coated with a combination of polymers. In this embodiment, the acetaminophen chewable tablets do not exhibit the bitter and unpleasant taste normally associated with acetaminophen.

25 In other embodiments, taste-masked dosage forms comprised of a number of antibiotics, and other pharmaceutical agents are provided. In each of these embodiments, excipients and other additives may be added to aid solubility and/or compressibility.

-2-

An oral dosage form is the preferred route of administration of acetaminophen and other pharmaceutical compounds because it provides easy, low cost administration. However, patient compliance becomes an important factor, especially when administering pharmaceuticals to children. Children generally show poor compliance with non-chewable tablets. Traditional non-chewable tablets generally show poor compliance in children, because they have trouble swallowing whole tablets. Part of the solution to this compliance problem is the use of chewable tablets as the administration vehicle. Chewable tablets are quite common and popular for solving the compliance problem, but when bitter or unpleasant tasting active agents, such as acetaminophen, are to be incorporated into chewable tablets, there is a need to mask the taste of the drugs. Otherwise, whatever increased compliance is obtained by using a chewable tablet will be lost to the unpleasant taste.

Conventional taste-masking techniques, for example, sweeteners and flavoring agents, may often be used. However, when a particularly unpleasant tasting active agent is to be administered, such as acetaminophen, these traditional sweeteners or flavoring agents are not as effective as certain embodiments of the invention described herein.

Alternative approaches of the prior art include microencapsulating unpleasant tasting active agent in a coating of ethyl cellulose or a mixture of ethyl cellulose and hydroxypropyl cellulose or other cellulose derivatives to provide chewable taste-masked products. These prior art products, however, suffer from the disadvantage that the polymer coating releases the active agent in an inconsistent fashion. This may be due to a lack of an adequate amount of plasticizer in

-3-

prior art chewable capsules to provide the necessary integrity for consistent release.

To provide chewable, taste-masked capsules with
5 consistent release qualities microencapsulation with cellulose derivatives requires a plasticizer, for example, polyethylene glycol, among others, in adequate amounts to soften the coating and provide elasticity, or chewability. Elastic qualities are highly desirable in
10 taste-masked microcapsules, because these qualities aid the capsule to resist fracture or rupture during chewing.

In one aspect of this invention, adequate supplies of
15 plasticizer are incorporated into the polymeric cellulose coating to provide chewable capsules of greater integrity, i.e., the ability to avoid rupture or fracture during chewing than prior art chewable cellulose coated capsules.

20 In the second aspect of this invention, it has surprisingly been found that the incorporation of adequate amounts of a low temperature film forming polymer with cellulose polymers or other high
25 temperature film forming polymers into the polymeric coating of a microcapsule will provide superior elastic (chewable) and taste-masked characteristics.

From a manufacturing cost standpoint, it is desirable to
30 have chewable, taste-masked microcapsules that are large (0.25-1 mm in diameter), because larger microcapsules are easier to manufacture and package, and are less expensive to produce than are smaller microcapsules. However, an increase in size makes fracture during
35 chewing and the release of drug from the microcapsule more likely to occur especially when there is an inadequate amount of plasticizer or other component

-4-

included to provide elasticity. A larger sized microcapsule requires greater elasticity to minimize the likelihood that a fracture will occur and active agent will be released. There is therefore a need in the art 5 of pharmaceutical formulation to provide encapsulating coatings capable of being formulated into chewable microcapsules as large as about 1.5 mm., that will not release drugs during chewing.

10 Prior art chewable microcapsules also suffer from the disadvantage that they are formulated using a technique known as coacervation (phase separation). The coacervation technique itself suffers from certain disadvantages. First, the technique requires the use of 15 hydrocarbon and other flammable organic solvents, for example, cyclohexane, which are explosive and present problems in large scale manufacturing. Second, the technique is expensive, because of the additional costs associated with the regulatory compliance (EPA) relative 20 to the method aspect of the invention described herein. Third, the process is very sensitive, and sometimes leads to reproducibility problems.

It is therefore an object of this invention to provide 25 an improved orally active pharmaceutical composition that serves to taste-mask active agents. It is a further object of this invention to provide a chewable tablet or capsule that taste masks pharmaceutically active agents that are unpleasant in taste to increase 30 patient compliance, especially in children.

It is an additional object of this invention to provide a chewable taste-masked formulation that can provide immediate release of an active compound as soon as it 35 reaches the stomach. It is an additional object of this invention to provide a taste-masked formulation in "sprinkle" form that can provide immediate release of

-5-

active agent in the stomach, delayed release of the active agent in the upper intestinal tract (duodenum, jejunum, or ileum) or sustained release of the active agent.

5

It is an additional object of this invention to provide chewable tablets of acetaminophen which do not exhibit the bitter, unpleasant taste characteristic of acetaminophen.

10

It is a further object of this invention to provide a method of producing taste-masked chewable pharmaceutical formulations utilizing an aqueous based formulation and an efficient process relative to the prior art methods such as coacervation or conventional coating techniques.

Summary of the Invention

In accordance with the present invention, these and other objects are achieved by a pharmaceutical composition comprised of 1) a pharmaceutical core which is further comprised of a pharmaceutically active dose of a compound and, 2) a microencapsulating polymer which coats the pharmaceutical core and is capable of taste-masking the active compound. The polymer coating maintains its integrity, i.e., does not fracture and release active when tabletted and/or chewed, and can provide immediate release of the active compound in the stomach, or alternatively, in certain embodiments, can release the active agent in the upper intestinal tract or in sustained release fashion. Additionally, the polymeric coating compositions or the pharmaceutical core may contain diluents, fillers, bulking agents, and plasticizers. The polymeric coatings may also contain pigments and opacifiers to promote compliance and enhance the storage stability of light sensitive active agents.

-6-

The formulations of the present invention include pharmaceutically effective amounts of an active agent microencapsulated in a polymeric coating. In preferred chewable embodiments of this invention, the coating is
5 insoluble or alternatively, non-swellable in the pH range that exists in the mouth. The effect of this insolubility or absence of swelling within the pH range of the mouth is to prevent release of the active agent in the mouth. Additionally, the coating may simply be
10 of a character that will not release active agents in the limited amount of fluid that exists in the mouth during chewing. Alternatively, the pharmaceutical core size may be kept to a minimum (10 um to 100 um) and microencapsulated to provide pharmaceutical "sprinkles".
15 These can be used on food and in drinks to provide an alternative administrative vehicle having immediate, enteric or sustained release characteristics.

The microcapsules of the present invention are
20 preferably of a size and elastic character that will not fracture during chewing. After the microcapsules are swallowed, the low pH environment of the stomach or simply the large volume of aqueous fluid will dissolve or swell the polymeric coating and allow the
25 encapsulated active agent to be released immediately, i.e., within a period of at most about two hours.

The taste-masked microcapsules of the present invention exhibit the following advantages. First, the
30 microcapsules may be formulated in an aqueous system. Second, the microcapsules have characteristics which allow them to withstand chewing. Third, the microcapsules can be produced to release active agents rapidly, in the upper intestinal tract, or in sustained
35 release fashion. Fourth, the production of the microcapsules may be performed easily, accurately, and consistently, thus eliminating the reproducibility

-7-

problems of the prior art methods.

Detailed Description of the Invention

5 The present invention comprises formulations of taste-masked microcapsules which further comprise 1) a polymeric coating that may provide chewable taste-masked characteristics, and 2) a pharmaceutical core of active ingredients. Both the polymeric coating and the
10 pharmaceutical core may further comprise diluents, fillers and other pharmaceutical additives which may effect the rate of release of active agent(s) from the microcapsule.

15 Preferably, the polymeric coating composition is comprised of a mixture of polymers differing in physicochemical properties. Each of the polymers in the mixture is preferably dispersible in water so as to take advantage of aqueous formulation techniques. Aqueous-based coating systems are safe and make regulatory
20 compliance (EPA) relatively easy compared to non-aqueous based coating systems. A number of polymeric coatings that can provide an elastic microcapsule and will not release active agent in the mouth when chewed are
25 contemplated by the present invention.

A preferred coating composition is a mixture comprised of at least about 5% of a high temperature film forming polymer and about 5% of a low temperature film forming polymer based on the total weight of polymer in the
30 microcapsule coating. A high temperature film forming polymer or "hard" polymer is defined as a polymer that will form a film on a pharmaceutical core at a temperature of at least about 30°C. Examples of high
35 temperature film forming polymers useful in this invention include hydroxypropylmethyl cellulose, for example, Pharmacoat™ 606 brand from Shinetsu Corp.,

-8-

Tokyo, Japan, hydroxypropyl cellulose, for example, Klucel™ brand from Hercules Corp. Wilmington, Delaware, methylcellulose for example Methocel A™, from Dow Chemical, Midland, Michigan, ethylcellulose, for example 5 Ethocel™ brand from Dow Chemical Corp. and other aqueous polymeric dispersions such as Aquacoat™ Brand from FMC, Philadelphia, Pennsylvania and Surelease™ brand from Colorcon, West Point, Pennsylvania, polyvinyl alcohol, polyvinyl acetate, cellulose acetate butyrate, styrene 10 acrylate copolymers, for example Janocryl 138 (61°C film forming copolymer from S.C. Johnson, Racine, Wisconsin) and copolymers of acrylic acid esters, for example, the Eudragit™ Copolymers (Rohm Pharma GmbH Westerstadt, W. Germany): Eudragit™ L30D, Eudragit™ L100-55, Eudragit™ 15 E100, Eudragit™ RS(30D and 100D) and Eudragit™ RL(30D and 100D).

Eudragit™ copolymers that are preferred in embodiments of this invention include L30D, an anionic copolymer 20 based on polymethacrylic and acrylic acid esters (Methacrylic Acid Copolymer, Type C- in USP XXI/NF XVI) with a mean molecular weight of 250,000, E30D (also NE 30D), a neutral copolymer based on poly(meth) acrylic acid esters with a mean molecular weight of 800,000, and 25 Eudragit™ RS and RL copolymers based on poly(meth)acrylic acid esters containing a low content of quaternary ammonium groups (from tertiary amino alkyl methacrylate polymerized into the copolymer backbone) which provide for active agent permeability over a 30 widely ranging pH.

The polymeric coating may provide for immediate release characteristics, i.e., rapid release of the active agents in the stomach after a period of at most 2 hours, 35 enteric release, or sustained release characteristics, depending upon the type and amount of polymer selected and the mode of administration. When the microcapsules

-9-

are formulated into chewable, taste-masked oral tablets or capsules, the formulations provide for immediate, rapid release in the stomach. "Sprinkle" formulations may provide for immediate release, enteric release, or 5 sustained release.

The chewable polymeric coating providing immediate release i.e., within two hours after ingestion may be comprised of a pharmaceutically compatible high 10 temperature film forming polymer that is water insoluble or not swellable within the pH range (about 5.5-6.5) and/or the liquid content of the mouth and will not release the active agent in the mouth, but will dissolve or change in physical character in the stomach, for 15 example, swell or become more porous, thus releasing drug. Examples of polymers which may be used in this manner include acid sensitive polymers, and polymers that may be solubilized at low pH after chewing for example, Eudragit E100™ (soluble at pH 2-5) or swell at 20 low pH, for example, Eudragit™ RL and RS, thus releasing active agent in the stomach after chewing.

Another preferred high temperature film forming acrylic resin polymer that releases active agent rapidly is 25 Eudragit L30D. Although Eudragit L30D is soluble at pH's in the mouth and insoluble at pH's of the stomach, it has found usefulness in chewable, taste-masked immediate release formulations of the present invention. This usefulness may stem from the lack of liquid in the 30 mouth, or may be the result of elastic qualities that Eudragit™ L30D acquires when formulated in combination with a plasticizer, or preferably, with Eudragit™ E30D.

Any of the above described polymers may be used alone or 35 in combination for microencapsulation. However, to make capsules of the required elasticity, plasticizers must be incorporated into the coatings. Plasticizers useful

-10-

to provide the requisite elasticity include polyalkylene glycols, for example polyethylene glycol, triacetin, (glyceryl triacetate from Eastman Kodak, Rochester, New York) vinyl pyrrolidone, diethyl phthalate, 5 dibutylsebacate, and esters of citric acid, among others. Generally, the plasticizers comprise between about 2% and about 50% by weight of polymer and plasticizer combined, preferably between about 5 and 15% by weight and most preferably about 10% by weight of the 10 polymer and plasticizer combined.

Alternatively, a low temperature film forming polymer characterized as a soft, plasticizer-like polymer may be used alone, or in combination with any of the above- 15 described "hard" polymers to produce a polymeric coating that is elastic, maintains its integrity during chewing, and may be easily formulated into microcapsules when chewable ranging in size form about 10 microns up to about 1.5 mm in diameter. A low temperature film 20 forming polymer or "soft" polymer is a polymer which forms a polymeric film at a temperture below about 25°C. A preferred "soft" polymer is a copolymer of methacrylic acid esters. A preferred polymethacrylic acid ester copolymer having a mean molecular weight of 800,000 is 25 Eudragit E 30D (Rohm Pharma). Another example of a low temperature film forming polymer useful in aspects of this invention is Janocryl 77 (styrene acrylate with a film forming temperature of 20°C, available from S.C. Johnson, Racine, Wisconsin).

30 The soft polymer and hard polymer may be combined to form a chewable, elastic microcapsule exhibiting immediate release characteristics. These polymers release the active agent as a function of the pH change 35 or as a function of the increased volume of liquid in the stomach or by a diffusion process. The microcapsules preferably do not fracture while in the

-11-

mouth. Immediate release is particularly useful when orally administering active agents that are readily absorbed from the stomach or do not require a gradual release of the active agent over time. This approach 5 has been shown to be particularly effective with active agents that are absorbed from the stomach, for example, acetaminophen.

A particularly preferred combination of polymers that 10 provides the above-mentioned immediate release characteristics in the stomach is a mixture of two co-polymers, the copolymer of methacrylic acid and methacrylate, for example Eudragit™ L 30D, and the copolymer of (meth)acrylic acid ester, for example, 15 Eudragit™ E 30D (NE30D). It has surprisingly been found that the combination of these two copolymers provides microencapsulated capsules exhibiting favorable taste-masking and chewable qualities, yet provides immediate release when exposed to the stomach juices. This is an especially surprising characteristic, because Eudragit™ 20 L30D when formulated alone in non-chewable capsules releases the active agent in the small intestine, not the stomach.

25 Though not willing to be bound by theory in limiting the scope of this invention, it appears that the above-described immediate release characteristics of the combination of Eudragit™ L30D and E30D (NE30D) are the result of an interaction between the two copolymers that 30 results in immediate release in the stomach, yet provides the necessary elasticity and integrity for taste-masking in a chewable tablet.

35 Alternatively, microcapsules exhibiting sustained release characteristics may be formulated as tablets and capsules, or as "sprinkles" for use on food or in drink. The polymers that are preferred for use in the sustained

-12-

release aspect of this invention include those polymers which are soluble or swellable at a pH above 5, or polymers that are slowly permeable regardless of pH. Permeable acrylic copolymers, for example, Eudragit™ RS 5 and RL polymers are especially useful and are preferred. It is also possible to combine polymers with the above-described characteristics.

Depending upon the release characteristics required, it 10 is also possible to combine more than two polymers to form a microcapsule. For example, one preferred approach may be to combine a polymer that releases active ingredient at a low pH, i.e., a pH that occurs in the stomach environment, with a polymer that releases 15 drugs at a pH found in the small intestine (about 5.5-7.5) and a polymer that is permeable regardless of the pH of the surrounding environment.

Another effective approach may be to provide more than 20 one type of microcapsule each differing in release qualities and differing as to the release sites. For example, a microcapsule coated with a polymer that releases an active agent at low pH can be combined with a microcapsule that releases active agent at a higher pH 25 in the small intestine and/or a microcapsule that releases agent regardless of pH. This will result in a formulation that provides a bolus dose of an active agent to rapidly increase plasma concentration of active to effective levels and a sustained release of active to 30 maintain the blood levels at the effective levels.

Particularly preferred embodiments of the taste-masked sustained release microcapsules are comprised of a combination of Eudragit™ RS and RL (low and high 35 permeability trimethyl ammonium ethyl methacrylate copolymers) and Eudragit™ E30D or a combination of Eudragit™ L30D and Eudragit E30D. The amount of low

-13-

permeable RS and high permeable RL copolymer can be varied as a function of the release characteristics and pharmacokinetics of the active agent. Likewise, the amount of Eudragit™ L30D and Eudragit™ E30D varies as

5 function of the release characteristics and pharmacokinetics of the active agent. The release characteristics of the active agent from the polymeric coating will be affected by the physicochemical character of the active agent (particle size,

10 crystallinity, solubility/lipophilicity). These polymers may lose their sustained release characteristics when chewed for a sustained period of time, and are therefore not contemplated for use in the chewable tablet as part of this invention. However,

15 sustained release qualities of these polymer combinations are maintained in the "sprinkle" form and the non-chewable capsule/tablet aspects of this invention.

20 For the chewable tablet, capsule or sprinkle aspect of this invention it is preferred that each of the high temperature film forming polymers be combined with a low temperature film forming polymer, for example, Eudragit™ E30D so that the coating will have the required

25 elasticity and integrity to endure chewing without fracturing and releasing active agent.

The polymeric coating described in detail above encapsulates a core comprised of, in part, a

30 pharmaceutically active compound. The taste-masking embodiment of the present invention may be used with virtually any active agent, or agent combination, except those that are chemically incompatible with the polymers used. The taste-masking aspect of this invention is, of course, of greatest utility for those compounds that are especially bitter tasting and cannot be taste-masked by more traditional means. The taste-masking microcapsules

-14-

are especially useful for bitter or unpleasant tasting drugs, for example, a number of antibiotics including erythromycin, penicillin, ampicillin, among others, as well as other active agents for example, acetaminophen,
5 dextromethorphan, cimetidine, pseudoephedrine, diphenhydramine, spironolactone, chlorpheniramine, theophylline, and phenylbutazone among others and any suitable salts thereof.

10 An especially preferred embodiment of this invention includes acetaminophen as the active agent in a chewable tablet form of administration coated with a 50:50 mixture of Eudragit™ L30D and E30D copolymers. Acetaminophen has long been a preferred and highly
15 successful analgesic and antipyretic agent. It is the analgesic/antipyretic agent of choice, preferred to aspirin, especially in children, because unlike aspirin, acetaminophen does not precipitate Reye Syndrome in children.
20 In many embodiments of this invention a diluent or bulking agent is preferably added to the core material. Acceptable diluents useful in embodiments of the present invention include dextrose, sorbitol, sucrose, lactose,
25 and mannitol, urea, salts, for example potassium chloride, sodium chloride, salts of phosphate, gelatin, starch, the natural and synthetic cellulose derivatives including, for example methyl-, ethyl-, propyl-, hydroxymethyl, hydroxyethyl, hydroxypropyl or
30 hydroxypropyl methyl cellulose, silica, polyvinyl alcohol, polyvinyl pyrrolidone and stearic acid and its salts for example magnesium stearate, among others. In general, the type and amount of diluent in the core material depends on the physicochemical characteristics
35 of the active agent to be released. Another factor determining the amount and type of diluent used is the type of release, i.e., rapid or sustained that will be

-15-

used to administer the active agent. The diluent generally comprises from about 0.1% to about 95% by weight of the core material, and preferably comprises between about 10% and 35% by weight of the core.

5

The pharmaceutically active core can be produced by a number of different prior art methods, but four approaches are preferable. In the first approach, a pharmaceutically active drug (in powder form) is first 10 placed in a fluidized bed equipment (Glatt, model GPCG-5, Glatt Air techniques, Inc. Ramsey, New Jersey) and thereafter, a spray binder solution or suspension comprised of, for example, polyvinyl pyrrolidone, starch, hydroxypropylmethyl cellulose or 15 microcrystalline cellulose (Avicel, from FMC) among other excipients in a pharmaceutically acceptable solvent for example water, 95% ethanol, or acetone, among others is sprayed onto the powder, formed into granules and then dried until the solvent is evaporated. 20 The drying temperature may vary over a broad range, but cannot be so high as to render the active agent inactive.

A second approach is to take powdered or granular active 25 agent, and diluent or bulking agent and form a wet mass utilizing water or a pharmaceutically acceptable solvent, for example water, ethanol or propylene carbonate. The mixture is mixed (Hobart mixer) until a wet mass or dough is formed. The wet mass is then 30 placed in an extruder (for example, Xtruder™ by LUWA, Inc. Charlotte, North Carolina) and extruded as a long, thin strand. The mixture may then be dried or may be placed in a spheronizer, (Murmurizer™ LUWA, North Carolina) which makes a pharmaceutical core that is 35 round and dry. The drying temperature may be any temperature that does not affect the activity of the active agent, and, depending upon the agent employed,

-16-

can vary over a broad range.

A third method for preparing the pharmaceutical core includes taking a pure drug in powdered or granular form 5 and mixing a lubricant, for example magnesium stearate or talc among others, with the active agent. The lubricated mixture can then be passed through a compactor, for example, Chilsonator™ by Fitzpatrick, Co., Elmhurst, Illinois compacted into a mass, and then 10 passed through a size reduction machine (Fitzmill™ by Fitzpatrick, Co.) and reduced to a suitable particle size.

A fourth method for preparing the pharmaceutical core 15 includes coating pure drug in granular or crystalline form with a polymeric coating.

The pharmaceutical core is coated with a taste-masking polymer or combination of polymers utilizing fluid bed 20 equipment. In the method of the present invention commercially available pharmaceutical granules (U.S.P. grade) of an active agent, or a pharmaceutical core produced by one of the previously disclosed methods, are placed in a fluid bed equipment utilizing, either a 25 Wurster insert (bottom spray mode), a conventional granulating insert (top spray mode), or in a rotary granulator (tangential spray mode). The polymeric coating is dispersed in water or water-miscible solvents, for example ethyl alcohol, acetone, isopropyl 30 alcohol or mixtures of these solvents, among others along with plasticizers, pigments, anti-foaming agents for example, silicone compounds and lubricants, for example talc or magnesium stearate to provide a smooth surface. In addition a lacquer coating may be added in 35 certain embodiments using the Eudragit™ acrylic resins. Plasticizers useful in certain polymeric coatings include propylene glycol, triacetin, vinylpyrrolidone,

-17-

diethyl phthalate, dibutylsebacate, and citric acid esters. In general, the plasticizers, when used, comprise about 2% to about 50% by weight of the polymeric coating, and preferably comprise about 7% to 5 about 15% of the coating. In many cases, the plasticizer preferably comprises about 10% by weight of the polymeric coating. In polymeric coatings utilizing a low temperature film forming polymer, for example, Eudragit™ E30D, or Janocryl™ 77, a plasticizer may be 10 used, but is generally not used.

For pigments, titanium dioxide, iron oxide, and various color pigments including vegetable dyes may be used. As a general rule, the particle size of the pigments is 15 preferably between 5 and 10um, and generally should not exceed 15um. Pigments are preferred when formulating chewable, taste-masked capsules because compliance may be enhanced when a capsule is attractively colored. Pigments and opacifiers are especially preferred for 20 stabilizing and enhancing the shelf life of pharmaceutical actives that are light sensitive or unstable. When pigments or opacifiers are used, it is sometimes preferred that non-ionic plasticizers, for example, Tween 60 and 80, polyvinylpyrrolidone and 25 polyethylene glycol, among others, be used. The amount of plasticizers used may vary, but should generally not exceed about 50%.

Once the pharmaceutical core has been coated it can then 30 be encapsulated in a hard gelatin capsule, further coated with candy coating or pressed into tablet form or presented as a "sprinkle" dosage form. The encapsulation processes are standard and well known in the pharmaceutical formulation art. The microcapsules 35 may be encapsulated or tabletted along with flavorants and sweeteners to aid compliance. The sweeteners and flavorants encapsulated or tabletted along with the

-18-

microcapsules are preferably powders, but where possible, formulations may include syrups or doughy mixtures. Preferred sweeteners include artificial sweeteners, for example, saccharin and cyclamates, the 5 sweetener aspartame, including mixtures of aspartame and saccharin, and natural sweeteners including sucrose, fructose and glucose, among a number of mono- and disaccharides. Preferably, the sweetener comprises about 0.02% to about 75% by weight of the total tablet, 10 depending upon the sweetener used. Of course, the amount of aspartame and saccharin used will generally be much smaller than the other sweeteners mentioned above and preferably will be less than about 0.5% of the total weight of the capsule to be administered.

15 Preferred flavorants useful in certain aspects of the present invention include cherry, grape, strawberry, chocolate, vanilla, spearmint, mocha, and cola among other flavorants. The amount of flavorant used in the 20 present invention is that amount which provides a pleasant flavor and increases compliance but, in general is at most 2% by weight of the composition.

The chewable taste-masked capsules or tablets are 25 administered in standard manner, the capsules or tablets are placed in the mouth, chewed, and then swallowed. The "sprinkle" form may be placed or sprinkled on cereal and other foods or in drinks and ingested. Non-chewable taste-masked capsules/tablets are simply administered by 30 swallowing without chewing.

A further aspect of this invention is the method for producing the taste-masked microcapsules. In general, the method comprises dispersing coating polymers and 35 other additives in an aqueous vehicle, spraying the coating mixture, drying the coated pharmaceutical core and then pressing the microcapsule into tablets and

-19-

encapsulating the microcapsule in hard gelatin.

In a particularly preferred aspect of the method of this invention Eudragit™ E30D and Eudragit™ L30D is mixed in 5 a 1:1 weight ratio, and sprayed onto fluidized acetaminophen pharmaceutical cores comprised of granular acetaminophen.

The preferred amount of applied coating is 20 to 30% of 10 the total weight of the dispersion when the coating is to be applied by the bottom spray techniques and tangential spray technique and 30 to 40% of the total weight of the dispersion when the coating is to be applied by the top spray technique.

15 Illustrating the invention are the following examples. These examples are for aiding the understanding of the invention, and are not to be construed as limiting the invention to their details.

20 A mixture consisting of Eudragit L30D and Eudragit E30D in equal portions (50:50) is sprayed onto the fluidizing acetaminophen particles. Eudragit™ L30D supplied as an aqueous dispersion containing 30% w/w of dry lacquer 25 substance (Rohm-Pharma) is mixed with Eudragit™ E30D, also supplied as a 30% w/w dispersion in a 1:1 ratio and placed in a suitable container and sprayed onto the fluidized particles using Glatt™ equipment (model GPCG5 Glatt Air Techniques, Ramsey, New Jersey).

30 Although a 1:1 mixture of Eudragit™ E30D and Eudragit™ L30D is most preferred, ratios ranging from 30 to 70% Eudragit™ E30D and 30 to 70% Eudragit™ L30D are also preferred. Ratios ranging from 5 to 95% Eudragit™ E30D 35 and about 5 to 95% Eudragit™ L30D are also useful.

The preferred amount of applied coating is 20 to 30% by

-20-

weight of the dispersion when applied by the bottom spray or tangential spray technique and 30 to 40% by weight of the dispersion when applied by the top spray technique. The preferred uncoated acetaminophen
5 particle size range is 150 to 300 microns.

Example 1. Preparation of Coated Taste-Masked Acetaminophen Particles

		(Top Spray)	(Bottom Spray)	(Tangential Spray)
10	Acetaminophen granular, USP	4.0kg	4.0k	4.0kg
	Eudragit L30D	2.666kg	2.0kg	2.0kg
	Eudragit E30D	2.666kg	2.0k	2.0kg

15 Preparation: Mix Eudragit L30D and Eudragit E30D at a slow agitation and spray while stirring onto the fluidized acetaminophen particles. Dry at a suitable temperature below about 60°C.

20 Example 2. Preparation of Chewable Tablets

	Coated Acetaminophen	415g (77.1% potent)	384g (83.3% potent)
	Inactive blend	1104g	1132g
25	Lubricant	15.6g	15.6g
	(magnesium stearate or stearic Acid)		

30 Preparation: Combine inactive ingredients and lubricant together and mix well. Add acetaminophen and mix until homogeneous for about five minutes in a planetary mixer (Hobart mixer). Compress to a tablet weight of 383 mg or to a weight which would provide the desired amount of acetaminophen per tablet. The inactive blend consists
35 of commonly used tablet excipients such as mannitol, sorbitol, microcrystalline cellulose, fructose, sweetener and flavors.

-21-

Claims:

1. A taste-masked pharmaceutical composition comprising: a) a core comprising a pharmaceutically active agent; and b) a polymer mixture coating said core comprised of a mixture of at least 5% by weight of a high temperature film forming polymer and at least 5% by weight of a low temperature film forming polymer.
2. The composition according to claim 1 wherein said high temperature film forming polymer is selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, ethyl cellulose, polyvinyl alcohol, polyvinyl acetate, cellulose acetate butyrate, and an acrylic acid ester copolymer.
3. The composition according to claim 2 wherein said acrylic acid ester copolymer is comprised of the reaction product of (meth)acrylic acid and at least one acrylic compound selected from the group consisting of methacrylic acid, acrylic acid, acrylic acid ester, and methacrylic acid ester.
4. The composition according to claim 1 wherein said low temperature film forming polymer is selected from the group consisting of EUDRAGIT E30D, and JANOCRYL 77.
5. The composition according to claim 1 wherein said high temperature film forming polymer is selected from the group consisting of JANOCRYL 138, EUDRAGIT E100, L30D, RS30D and RL30D and said low temperature film forming polymer is selected from the group consisting of EUDRAGIT 30D and

-22-

JANOCRYL 77.

6. The composition according to claim 1 wherein said core further comprises a diluent.
7. The composition according to claim 1 wherein said polymer coating further comprises a plasticizer.
8. The composition according to claim 6 wherein said plasticizer is selected from the group consisting of polyethylene glycol, triacetin, vinylpyrrolidone, diethyl phthalate, dibutylsebacate, and citric acid esters.
9. The composition according to claim 1 wherein said pharmaceutically active agent is unpleasant tasting.
10. The composition according to claim 8 wherein said pharmaceutically active agent is selected from the group consisting of erythromycin, penicillin, ampicillin acetaminophen, dextromethorphan, cimetidine, pseudoephedrine, diphenhydramine, spironolactone, chlorphenisamine, theophylline, and phenylbutazone.
11. A chewable taste-masked pharmaceutical composition comprising:
 - (a) a core comprising a pharmaceutically active agent; and
 - (b) a polymer mixture coating said core comprised of a mixture of at least 5% by weight of a high temperature film forming polymer and at least 5% of a low temperature film forming polymer.
12. The composition according to claim 9 wherein said

-23-

high temperature film forming polymer is selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, ethyl cellulose, polyvinyl alcohol, polyvinyl acetate, cellulose acetate butyrate, an acrylic acid ester and a styrene acrylate.

13. The composition according to claim 10 wherein said acrylic acid ester copolymer is comprised of the reaction product of (meth)acrylic acid and at least one acrylic compound selected from the group consisting of methacrylic acid, acrylic acid, acrylic acid ester and methacrylic acid ester.
14. The composition according to claim 9 wherein said high temperature film forming polymer is selected from the group consisting of EUDRAGIT L100-55, L30D, RS30D, RL30D and JANOCRYL 138 and said low temperature film forming polymer is selected from the group consisting of EUDRAGIT E30D and JANOCRYL 77.
15. A process for making a taste-masked chewable composition containing a pharmaceutically active compound comprising the steps of:
 - (a) suspending in an aqueous based solution at least about 5% by weight of the total weight of polymers in suspension of an aqueous dispersible high temperature film forming polymer and at least about 5% by weight of an aqueous dispersible low temperature film forming polymer;
 - (b) spraying the suspension from (a) onto a pharmaceutical core comprised of at least one pharmaceutically active agent; and
 - (c) drying the sprayed core from (b).

-24-

16. The process according to claim 9 wherein said spraying is performed using a bottom spray technique.
17. The process according to claim 9 wherein said spraying is performed using a top spray technique.
18. The process according to claim 9 wherein said spraying is performed using a tangential spray technique.

INTERNATIONAL SEARCH REPORT

International Application No PCT/US87/03068

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ¹

According to International Patent Classification (IPC) or to both National Classification and IPC
 IPC(4): A61K 9/28 9/32 9/36 9/50 9/56 9/58 9/62
 U.S. 424/474,475,480,482,490; 424/494,495,497 427/3

II. FIELDS SEARCHED

Minimum Documentation Searched ⁴	
Classification System	Classification Symbols
U.S.	424/474,475,480,482,490,494,495,497 427/3
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁵	

III. DOCUMENTS CONSIDERED TO BE RELEVANT ^{1,4}

Category ⁶	Citation of Document, ^{1,6} with indication, where appropriate, of the relevant passages ^{1,7}	Relevant to Claim No. ^{1,8}
T/A	U.S., A, 4,710,384 (ROTMAN) 1 December 1987 (See the entire document).	1 to 14
P/A	U.S., A, 4,656,027 (SJOOVIST) 7 April 1987 (See the entire document).	1 to 14
A	U.S., A, 4,587,118 (HSIAO) 6 May 1986 (See the entire document).	1 to 14
A	U.S., A, 4,101,651 (KOBAYASHI ET AL) 18 July 1978 (See the entire document).	1 to 14
A	U.S., A, 4,016,254 (SEAGER) 5 April 1977 (See the entire document).	1 to 18
A	U.S., A, 3,860,733 (MORSE ET AL) 14 January 1975 (See the entire document).	1 to 14
A	U.S., A, 3,821,422 (MORSE ET AL) 28 June 1974 (See the entire document).	1 to 14

* Special categories of cited documents: ^{1,6}

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search ¹	Date of Mailing of this International Search Report ¹
10 FEBRUARY 1988	10 MAR 1988
International Searching Authority ¹ ISA/US	Signature of Authorized Officer ^{1,9} <i>Shep K. Rose</i> Shep K. Rose

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

A	U.S., A, 3,775,537 (LEHMANN ET AL) 27 November 1973 (See the entire document).	1 to 18
A	U.S., A, 3,520,970 (LEHMANN ET AL) 21 July 1970 (See the entire document).	1 to 18

V. OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹⁰

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. Claim numbers because they relate to subject matter ¹² not required to be searched by this Authority, namely:

2. Claim numbers because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out ¹³, specifically:

VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ¹¹

This International Searching Authority found multiple inventions in this international application as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims covered by claim numbers:

4. As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- The additional search fees were accompanied by applicant's protest.
- No protest accompanied the payment of additional search fees.